News

Filter

Current filters:

palifosfamide

Ziopharm's palifosfamide fails to meet endpoint in Ph III study

26-03-2013

US drug developer Ziopharm Oncology (Nasdaq: ZIOP) saws its shares plunge $3.21 to $1.92 after it said…

OncologypalifosfamidePharmaceuticalResearchZiopharm Oncology

COMPANY SPOTLIGHT

Menarini

Back to top